Abstract: A clear, photocurable coating composition to be applied over wet nail polish on a nail for binding with the wet nail polish upon exposure to ultraviolet light, consisting of: between 5% and 50% by weight of a film-forming polymer selected from the group consisting of:i) cellulose estersii) acrylic polymers,between 2% and 15% by weight of a photoinitiator selected from the group consisting of:i) benzophenoneii) alkylphenyl ketone, andiii) cyclohexylphenyl ketone;and between 40% and 85% by weight of a photoreactive monomer selected from the group consisting of methacrylic acid esters.

Abstract: A photocurable coating composition to be applied directly onto a nail surface and is rapidly curable upon exposure to ultraviolet light, comprising between 5% and 65% by weight of a film-forming polymer selected from the group consisting essentially of:i) cellulose derivativesii) acrylic polymers;between 2% and 20% by weight of a photoinitiator selected from the group consisting essentially of:i) acetophenoneii) benzophenoneiii) alkylphenyl ketoneiv) cyclohexylphenyl ketone;and between 10% and 90% by weight of a photoreactive monomer selected from the group consisting essentially of:i) methacrylic acid estersii) diesters of methacrylic acid,where the percentages by weight are based on the composition total weight.

Abstract: A GaAs circuit structure is described which interposes a Langmuir-Blodgett (L-B) layer between the substrate and a conductive contact. The thickness of the layer is controlled to determine the operating characteristics of the device. The head group of the L-B molecule is chosen so that it passivates the surface states of the particular GaAs substrate being used. Certain preferred acids and amino head groups are disclosed. The L-B layer has been found to both increase the gate barrier height for an FET, and to passivate dangling bonds and surfaces defects in the GaAs substrate to enable inversion mode operation. Specific FET and diode devices are described.

Abstract: Histamine derivatives are disclosed which find use as effect and tissue-specific immune modulators. Specifically, the primary terminal nitrogen in histamine is derivatized to introduce a variable length side chain having 0 to 1 branch of from 1 to 3 carbons; 0 to 2 non-oxo-carbonyl groups; 0 to 4 heteroatoms, other than the non-oxo carbonyl oxygen; 0 to 1 aryl or alkyl-aryl group; and 0 to 1 functionally bound amino acid, polypeptide, or protein or derivative thereof.

Abstract: Molecular structures of .beta.-adrenergic antagonists are modified to produce biologically active compounds. The .beta.-antagonists are modified to form molecules of the general structure: ##STR1## wherein R is most generally R"--OCH.sub.2 --, and in some instances is R"--, and R"=an aryl or substituted aryl moiety; R'=--H, --CH.sub.3, or a short chain alkyl moiety; and Y=--OH, or more usually, --OAX or --NHAX, where A=an alkyl, aryl, or aralkyl moiety, and X=a terminal grouping, such as --CH.sub.3, --CF.sub.3 or --(CH.sub.2).sub.n COOH; or AX may be a carrier moiety consisting of a defined peptide or protein.

Abstract: Molecular structures of .beta.-adrenergic antagonists are modified to produce biologically active compounds. The .beta.-antagonists are modified to form molecules of the general structure: ##STR1## wherein R is most generally R"--OCH.sub.2 --, and in some instances is R"--, and R"=an aryl or substituted aryl moiety; R'=--H, --CH.sub.3, or a short chain alkyl moiety; and Y=--OH, or more usually, --OAX or --NHAX, where A=an alkyl, aryl, or aralkyl moiety, and X=a terminal grouping, such as --CH.sub.3, --CF.sub.3 or --(CH.sub.2).sub.n COOH; or AX may be a carrier moiety consisting of a defined peptide or protein.

Abstract: Histamine derivatives are disclosed which find use as effect and tissue-specific immune modulators. Specifically, the primary terminal nitrogen in histamine is derivatized to introduce a variable length side chain having 0 to 1 branch of from 1 to 3 carbons; 0 to 2 non-oxo-carbonyl groups; 0 to 4 heteroatoms, other than the non-oxo carbonyl oxygen; 0 to 1 aryl or alkylaryl group; and 0 to 1 functionally bound amino acid, polypeptide, or protein or derivative thereof.